

ACTHIV
2009



AMERICAN CONFERENCE FOR THE TREATMENT OF HIV

MAY 15-17, 2009

HYATT REGENCY DENVER — DENVER, COLORADO

CONFERENCE PROGRAM

This educational activity is jointly sponsored by the American Academy of CME, Inc. and the Foundation for the American Conference for the Treatment of HIV. The American Conference for the Treatment of HIV is supported by funding from the Office of AIDS Research of the National Institutes of Health. This educational activity is supported by educational grants from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, and Roche.



ACTHIV
THE AMERICAN CONFERENCE
FOR THE TREATMENT OF HIV

SUPPORTERS

NATIONAL INSTITUTES OF HEALTH



The American Conference for the Treatment of HIV is supported by funding from the Office of AIDS Research of the National Institutes of Health. This educational activity is supported by educational grants from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline and Roche.

COLLABORATING FEDERAL AGENCIES

- ▶ Centers for Disease Control and Prevention
- ▶ U.S. Department of Health and Human Services
- ▶ Federal Bureau of Prisons
- ▶ Health Resources and Services Administration
- ▶ National Institutes of Health
- ▶ National Institute on Drug Abuse
- ▶ National Institute of Child Health and Human Development
- ▶ National Cancer Institute
- ▶ U.S. Department of Veterans Affairs

TABLE OF CONTENTS

CONFERENCE LEADERSHIP	2
ABOUT ACTHIV 2009	4
WELCOME FROM THE PROGRAM COMMITTEE CO-CHAIRS	5
WELCOME FROM THE PRESIDENT OF THE BOARD	6
FLOORPLANS	7
SCHEDULE-AT-A-GLANCE	8
REGISTRATION	9
MEALS & REFRESHMENTS	9
SPECIAL EVENTS	9
GENERAL INFORMATION	10
TRANSPORTATION & PARKING	11
PRESENTER INFORMATION	11
ACCREDITATION	12
EXHIBIT HALL	13
CONFERENCE AGENDA	14
POSTER SESSIONS	18
FACULTY	22
FINANCIAL AND OFF-LABEL DISCLOSURE INFORMATION	23
NOTES	28

CONFERENCE MANAGEMENT

Ellen Shortill, Meeting Manager
Lauren Bajorek, Program Manager
Amy Roth, Grants & Symposia Manager
C.J. Stermer, Exhibits & Sponsorship Manager
Chezka Solon, Registration & Housing Manager

ACTHIV 2009 c/o Courtesy Associates
2025 M Street NW, Suite 800
Washington, D.C. 20036
Phone: +1 (202) 973-8658
Fax: +1 (202) 331-0111
Email: acthiv@courtesyassoc.com

LEADERSHIP

BOARD OF DIRECTORS

President

Douglas Ward, MD, FACP
Dupont Circle Physicians Group
Washington, DC

Melanie Thompson, MD
AIDS Research Consortium of Atlanta
Atlanta, GA

Secretary/Treasurer

Sharon Lee, MD
Southwest Boulevard Family Health Care Services
of Greater Kansas City
Kansas City, KS

2008-2009 PROGRAM COMMITTEE

Co-Chair

Victoria A. Cargill, MD, MSCE
National Institutes of Health
Office of AIDS Research
Bethesda, MD

Co-Chair

Kathleen E. Squires, MD
Jefferson Medical College
Thomas Jefferson University
Philadelphia, PA

Erika Aaron, CRNP, MSN
Drexel University College of Medicine
Division of Infectious Diseases and HIV Medicine
Philadelphia, PA

Gerald Friedland, MD
Yale University School of Medicine
AIDS Program
New Haven, CT

Arlene D. Bardeguez, MD, MPH
New Jersey Medical School
Department of Obstetrics, Gynecology & Women's Health
Newark, NJ

Donna Futterman, MD
Adolescent AIDS Program
Montefiore Medical Center
Albert Einstein College of Medicine
Bronx, NY

James Braun, DO
Physicians' Research Network, Inc.
New York, NY

Harold Henderson, MD
University of Mississippi Medical Center
Division of Infectious Diseases
Jackson, MS

Gina Brown, MD
National Institutes of Health
Office of AIDS Research
Bethesda, MD

Brian Hujdich, BA
CAEAR Foundation
Washington, DC

Tommy Chesbro, MHR, AASECT
Planned Parenthood of Arkansas and Eastern Oklahoma, Inc.
Tulsa, OK

John JD Juchniewicz, MCIS
American Academy of CME, Inc.
Skillman, NJ

Steven Deeks, MD
University of California, San Francisco
San Francisco, CA

Natalie Kirkwood, RN, BSN, JD
American Academy of CME, Inc.
Skillman, NJ

Judith Feinberg, MD
University of Cincinnati
Cincinnati, OH

Harry Lampiris, MD
San Francisco VA Medical Center / UCSF
San Francisco, CA

Brian Feit, MPA
U.S. Department of Health and Human Services
Health Resources and Services Administration,
HIV/AIDS Bureau
Rockville, MD

Kenneth A. Lichtenstein, MD
University of Colorado
Health Sciences Center
Division of Infectious Diseases
National Jewish Medical and Research Center
Denver, CO

PROGRAM COMMITTEE (CONTINUED)

Kenneth Mayer, MD

Brown University
Miriam Hospital
Providence, RI

Sondra L. Moylan, MS, RN

American Academy of CME, Inc.
Skillman, NJ

Tonia Poteat, MMSc, MPH, PA-C

Grady Infectious Disease Program
Decatur, GA

Anita E. Radix, MD, MPH

Callen Lorde Community Health Center
New York, NY

M. Keith Rawlings, MD

Peabody Health Center
AIDS Arms, Inc.
Dallas, TX

David Rimland, MD

Atlanta VA Medical Center
Decatur, GA

William R. Short, MD

Jefferson Medical College
Thomas Jefferson University
Philadelphia, PA

Glenn J. Treisman, MD, PhD

Johns Hopkins University School of Medicine
Department of Psychiatry and Behavioral Sciences
Department of Medicine
Baltimore, MD

Paul Volberding, MD

San Francisco VA Medical Center
University of California, San Francisco
San Francisco, CA

Andrea Weddle

HIV Medicine Association
Arlington, VA

Barbara A. Young, MSW, LCSW, LCADC, SAC

Consultant to American Academy of CME, Inc.
Monroe, NJ

FEDERAL SCIENTIFIC COLLABORATIVE PANEL

This conference is held in scientific collaboration with the following federal agencies and their representatives:

Songhai Barclift, MD

Health Resources and Services Administration
HIV/AIDS Bureau
Rockville, MD

Christopher Bates, MPA

U.S. Department of Health and Human Services
Washington DC

Jo Sheehan Brabson, BS, RN

Public Health Strategic Health Care Group
U.S. Department of Veterans Affairs
Washington, DC

John Brooks, MD

Centers for Disease Control and Prevention
Atlanta, GA

Lawrence Deyton, MSPH, MD

U.S. Department of Veterans Affairs
Office of Public Health and Environmental Hazards
Washington, DC

Robert Eisinger, PhD

National Institutes of Health
Office of AIDS Research
Bethesda, MD

Catherine Godfrey, MD

National Institutes of Health
National Institute of Allergy and Infectious Diseases
Bethesda, MD

Christopher M. Gordon, PhD

National Institutes of Health
National Institutes of Mental Health
Bethesda, MD

Newton E. Kendig, RADM

Health Services
Federal Bureau of Prisons
Washington, DC

Jag H. Khalsa, PhD

National Institutes of Health
National Institute on Drug Abuse
Division of Pharmacotherapies and
Medical Consequences of Drug Abuse (DPMC)
Bethesda, MD

Lynne Mofenson, MD

National Institute of Child Health and Human Development
Pediatric, Adolescent & Maternal AIDS Branch,
Eunice Kennedy Shriver
Rockville, MD

Mostafa Nokta, MD, PhD

National Cancer Institute
Rockville, MD

Ronald O. Valdiserri, MD, MPH

Public Health Strategic Health Care Group
U.S. Department of Veterans Affairs
Washington, DC

ABOUT ACTHIV 2009

The Foundation for the American Conference for the Treatment of HIV is a non-profit organization established in 2006 for the sole purpose of producing and executing a treatment education conference for front-line HIV care providers. The mission of the foundation and the goals of the conference are:

- ▶ To conduct a state-of-the-science meeting for primary clinical care providers (physicians, nurses, physician assistants, nurse practitioners, psychologists, pharmacists, et. al.)
- ▶ To translate the latest developments in HIV clinical science to the delivery of medical care to persons with HIV infection
- ▶ To learn from active clinical care providers about their experience in treating persons with HIV infection in order to advance clinical care and research.

GLOBAL LEARNING OBJECTIVES

After attending this conference, participants should be able to:

- ▶ Develop and implement an appropriate management plan for individuals living with HIV based on an evaluation of comorbidities, complications and special challenges.
- ▶ Address the difficulties of caring for treatment experienced patients with HIV, including dealing with drug-resistant virus, and the complications of long-term treatment.
- ▶ Incorporate approaches to maximize patient adherence with therapy and the reduction of viral transmission based on an understanding of the benefits of treatment.
- ▶ Integrate mental and sexual health and substance use assessment into clinical work with HIV+ patients.
- ▶ Develop skills to conduct patient assessments, examinations (and interventions, as indicated) in two of the following four areas: sexual history and related risk reduction counseling, female pelvic examination (with models), male-specific anal cytology for cancer screening, and smoking history and tobacco cessation counseling.



ACTHIV
THE AMERICAN CONFERENCE
FOR THE TREATMENT OF HIV

TARGET AUDIENCE

ACTHIV is designed for health care professionals who provide direct health care to persons with, or at risk for, HIV infection. This conference is open to individuals in both the public and private health care settings.

The target audience includes: physicians, nurses, nurse practitioners, physician assistants, pharmacists, social workers, psychologists, mental health and substance abuse workers, as well as other providers in frontline health care settings.

ADDITIONAL OBJECTIVES

The following additional objectives were identified for the HIV Basics session, which is targeted to those providers who are relatively new to HIV, care as well as those who have not provided care to persons with HIV infection in some time.

- ▶ Utilize appropriate clinical tests for guiding the care of individuals with HIV.
- ▶ Develop treatment strategies for individuals with HIV based on currently available guidelines.
- ▶ Incorporate strategies for remaining up-to-date on future modifications to the guidelines for managing the care of those with HIV
- ▶ Identify appropriate ARV regimens for newly diagnosed individuals with HIV based on current evidence

Learning objectives for individual talks can be found on the speaker evaluation form.

WELCOME TO ACTHIV 2009

WELCOME FROM THE PROGRAM COMMITTEE CO-CHAIRS

Welcome to the *American Conference for the Treatment of HIV* (ACTHIV).

We are delighted that you have decided to join us in exploring the excitement and challenges of caring for people living with HIV infection. This is our third meeting following two prior successful events, one in Atlanta and the other in Dallas. As the field of HIV management continues to evolve with new scientific discoveries, new drug classes and treatment breakthroughs with associated management challenges, we felt another meeting was needed.

The HIV news since our last meeting has been both daunting and encouraging. Additional epidemiologic methods and back calculations changed the estimate of HIV infections to a number most in the field did not find surprising, albeit troubling. The ongoing disparity in HIV incidence and transmission rates remains not only glaring, but troubling, especially in certain populations, such as MSM and women. Data from vaccine and microbicide trials remind us that the field still faces many challenges, and scientific questions, as we search for additional biomedical prevention strategies. Newer treatment options have improved the quality and quantity of life for those living with HIV infection, but sadly unequal access, differential treatment adherence rates, pre-existing conditions and side effects do not confer the same benefit for all. As our populations continue to age, they will present us with the challenge of managing HIV infection along with the medical problems associated with aging.

The news, however, has not all been bad. There have been additional agents added to the treatment armamentarium. Our evolving knowledge of the pathophysiology of HIV infection, including the pivotal role of the gut in the early stages of infection, offer potential avenues for therapeutic intervention. The demonstration of the effectiveness of prevention interventions provides us with options for reducing risk while working on more sustainable means of HIV protection. All of this in the context of total patient care and wellness, from routine health care maintenance and smoking cessation to medication adherence (and everything in between) has fallen under the purview of the HIV team. It is indeed a time of change for clinicians working in this field.

Supported by a number of federal, public and private agencies, this meeting is designed to address the team concept of HIV care. Dedicated clinicians have been integrally involved in planning ACTHIV and providers are the intended audience of this national conference. Certain ACTHIV sessions will utilize an electronic Audience Response System to encourage interaction and a dialogue among speakers and the audience. This year ACTHIV is presented with both single track plenary sessions and breakout sessions and multiple-track plenary formats, allowing all attendees to maximize their participation in the entire meeting.

We look forward to meeting with you and to hearing your insights, along with your colleagues, in this vitally important field.

Sincerely,



Victoria A. Cargill, MD, M.S.C.E.
Office of AIDS Research
National Institutes of Health
ACTHIV Program Committee Co-Chair



Kathleen E. Squires, M.D.
Jefferson Medical College of
Thomas Jefferson University
ACTHIV Program Committee Co-Chair

WELCOME FROM THE PRESIDENT OF THE BOARD

On behalf of the Board of Directors of The American Conference on the Treatment of HIV (ACTHIV), welcome to Denver!

In September, 2005, the inaugural Conference on the Treatment and Management of HIV Infection in the United States was held in Atlanta, Georgia. This conference was a cooperative project of ten federal agencies involved in the care of HIV, and was a great success. Subsequent to that meeting it was decided that the conference should be independent of the government, and so the not-for-profit Foundation for The American Conference on the Treatment of HIV was created.

The first "ACTHIV" conference was held in May 2007 in Dallas, Texas and continued the precedent of a clinically-oriented, state-of-the-art HIV conference. Over the last two years the foundation has worked with program co-chairs Kathleen Squires and Victoria Cargill, the program committee, and a panel of co-operating federal agencies to put together this week's second ACTHIV.

There are many conferences devoted to HIV, both national and international, but few of them are as uniquely focused on the clinical care of those living with HIV. ACTHIV is devoted to providing useful clinical information for those involved in frontline care of HIV. We hope that you will find the information presented at this conference beneficial in the day-to-day management and care of your patients.

Sincerely,




Douglas J. Ward, MD, FACP

President, Board of Directors


The American Conference on the Treatment of HIV

FLOORPLANS — HYATT REGENCY DENVER

THIRD LEVEL



FOURTH LEVEL



SCHEDULE - AT - A - GLANCE

Thursday, May 14	Time	Location
Registration Open	2:00 pm – 6:00 pm	Centennial Foyer
Friday, May 15	Time	Location
Registration	7:00 am – 7:00 pm	Centennial Foyer
Breakfast	7:30 am – 9:00 am	Centennial Ballroom E-H
<i>HIV The Basics</i>	8:00 am – 11:30 am	Capitol Ballroom 1-3
Morning Break	9:30 am – 10:00 am	Capitol Foyer
Exhibit Hall	7:30 am – 7:30 pm	Centennial Ballroom E-H
Luncheon	11:30 am – 12:45 pm	Centennial Ballroom E-H
<i>Poster Sessions 1 & 2</i>	11:30 am – 12:45 pm	Centennial Ballroom E-H
Opening Plenary Session: <i>HIV Infection in MSM of Color & HIV Infection in Women</i>	12:55 pm – 2:00 pm	Centennial Ballroom A-D
Session 1: <i>Special Challenges/Co-Morbidities/Complications</i>	2:00 pm – 5:00 pm	Centennial Ballroom A-D
Afternoon Break	3:20 pm – 3:30 pm	Centennial Foyer
Welcome Reception	5:30 pm – 7:30 pm	Centennial Ballroom E-H
Saturday, May 16	Time	Location
Registration	7:00 am – 5:00 pm	Centennial Foyer
Exhibit Hall	7:30 am – 4:00 pm	Centennial Ballroom E-H
Breakfast	8:00 am – 9:30 am	Centennial Ballroom E-H
Session 2: <i>Treatment Management</i>	9:00 am – 12:00 pm	Centennial Ballroom A-D
Morning Break	10:45 am – 11:00 am	Centennial Foyer
Luncheon	12:00 pm – 1:30 pm	Centennial Ballroom E-H
<i>Poster Sessions 3, 4 & 5</i>	12:00 pm – 1:30 pm	Centennial Ballroom E-H
Session 3: <i>Concurrent Sessions (offered two times)</i>		
<i>Sexual and Reproductive Health</i>	1:45 pm – 3:15 pm & 3:30 pm – 5:00 pm	Centennial Ballroom A-D
<i>Substance Abuse and Mental Health</i>		Capitol Ballroom 1-3
<i>Adolescent and Pediatric HIV</i>		Capitol Ballroom 4
<i>Viral Confection HIV/HBV/HCV</i>		Capitol Ballroom 5-7
Afternoon Break	3:15 pm – 3:30 pm	Centennial Foyer
Sunday, May 17	Time	Location
Registration	8:00 am – 11:00 am	Centennial Foyer
Breakfast	8:00 am – 9:30 am	Centennial Ballroom E-H
Session 4: <i>Skills Building Workshops (offered three times)</i>		
<i>Tobacco Cessation</i>	9:10 am – 9:50 am & 9:55 am – 10:35 am & 10:40 am – 11:20 am	Capitol Ballroom 1-3
<i>Cervical and Anal Paps in HIV-infected Men and Women – Practical Aspects</i>		Capitol Ballroom 4
<i>Prevention is Care” – How to Incorporate STD Screening and Prevention in HIV Care</i>		Capitol Ballroom 5-7
Closing Plenary: <i>Where Do We Go Next? Prevention of HIV Among Vulnerable Populations</i>	11:30 am – 12:00 pm	Centennial Ballroom A-D

REGISTRATION

REGISTRATION SERVICES

Thursday through Saturday

Level 3, Centennial Foyer

Attendees who registered online may check-in at the registration desk and pick up all meeting materials, including badges and the conference program. Attendees may register onsite during the hours listed below:

Thursday, May 14.....	2:00 pm – 6:00 pm
Friday, May 15.....	7:00 am – 7:00 pm
Saturday, May 16.....	7:00 am – 5:00 pm
Sunday, May 17	8:00 am – 11:00 am

RECEIPTS

All attendees who register online will receive a receipt/confirmation via email. Participants who register onsite will receive a paper receipt only if requested; otherwise a confirmation email will be sent to the email address provided.

ONSITE FEES:

Registration fees include access to oral sessions (including HIV The Basics), CME/CE credits, poster sessions, exhibit hall, breakfasts, lunches, breaks, receptions, and one copy of the conference program. Additional fees may be associated with CME/CE credits for the Satellite Symposium.

Meeting Registration*

Attendee	\$300
Student.....	\$225

*If you do not wish to apply for continuing education credits, \$50.00 will be deducted at time of payment from your total registration fee.

BADGES

Badges should be worn at all official functions of the meeting. Badge checkers will be stationed throughout the meeting site. Only those with full meeting registrations will be allowed into sessions.

If you forget or lose your badge, you may obtain a second badge at registration with proof of registration.

MEALS & REFRESHMENTS

Meeting registration includes all meals, receptions, and refreshments provided by ACTHIV 2009.

BREAKFAST

Level 3, Exhibit Hall, Centennial Ballroom E-H

Friday, May 15.....	7:30 am – 9:00 am
Saturday, May 16.....	8:00 am – 9:30 am
Sunday, May 17	8:00 am – 9:30 am

MORNING REFRESHMENT BREAK

Friday, May 15.....9:30 am – 10:00 am
Level 4, Capitol Foyer

Saturday, May 16.....10:45 am – 11:00 am
Level 3, Exhibit Hall, Centennial Foyer

LUNCHEON

Level 3, Exhibit Hall, Centennial Ballroom E-H

Friday, May 15.....	11:30 am – 12:45 pm
Saturday, May 16.....	12:00 pm – 1:30 pm

AFTERNOON REFRESHMENT BREAK

Level 3, Centennial Foyer

Friday, May 15.....	3:20 pm – 3:30 pm
Saturday, May 16.....	3:15 pm – 3:30 pm

SPECIAL EVENTS

WELCOME RECEPTION

Friday, May 15 • 5:30 pm – 7:30 pm
Level 3, Exhibit Hall, Centennial Ballroom E-H

Kick-off the conference week and join your colleagues for refreshments, hors d'oeuvres and great company at the ACTHIV 2009 Welcome Reception.

GENERAL INFORMATION

ACCESSIBILITY FOR REGISTRANTS WITH DISABILITIES

The meeting staff will work with attendees to provide reasonable accommodations for those who require special needs. To request assistance onsite, please check in at the Registration Desk located on Level 3, Centennial Foyer.

CAMERAS, RECORDING DEVICES, AND CELL PHONES

The use of cameras, recorders and/or cell phones is strictly prohibited during the oral and poster sessions. Limited use is allowed for Exhibitors in their own booth area. Personal photography is allowed at social functions.

CYBER CAFÉ

Computer terminals with complimentary Internet access will be provided to all for conference attendees, courtesy of the **National Institutes of Health, Office of AIDS Research**. Terminals will be available for access in the Exhibit Hall during Exhibit Hall hours only. Access will be granted on a first come first served basis; however, as a courtesy to fellow meeting attendees, we ask that you limit your time at the computer to 10 minutes.

PRINT-ON-DEMAND STATIONS

Due to popular demand and in our effort to remain environmentally conscious, Print-On-Demand Stations will be available for all attendees. Here you will be able to print handouts for sessions you plan to attend. The stations will be located in the *Centennial Foyer*. Please note that hard copy handouts will not be provided by ACTHIV.

LOST & FOUND

Lost & Found will be located at the Registration Desk, located on Level 3, Centennial Foyer.

BUSINESS CENTER

The business center is located in the main lobby of the Hyatt Regency Denver, adjacent to the front desk. The center is equipped with photocopying and fax services, as well as Internet access and shipping services. Hours of operation are Monday through Friday from 7:00 am to 7:00 pm.

FIRST AID


The Hyatt Regency security team is first-aid/CPR trained and is reachable using any house phone and dialing 55. *Perks*, located on the lobby level of the Hyatt Regency Denver has all basic First Aid needs, including pain relievers and band-aids.

MESSAGE/INFORMATION CENTER

A message board will be located in the Registration area (Level 3, Centennial Foyer) for the duration of the conference. Should you need to reach a fellow attendee, please place a message on the board. Attendees will not be paged.

ADDITIONAL PROGRAM BOOKS

Each registrant receives one copy of the Conference Program Book. Additional copies will be provided at the conclusion of the conference and will be handed out on a first come, first served basis. Please visit the Registration Desk for more information.



HOTEL

ACTHIV 2009 has one participating hotel, the Hyatt Regency Denver.

Hyatt Regency Denver
650 15th Street
Denver, CO, USA 80202
Phone: +1 (303) 436 - 1234
Fax: +1 (303) 486 - 4450

TRANSPORTATION & PARKING

LOCAL TRANSPORTATION

There are a number of transportation options to and from the airport and in and around the city of Denver. The estimated one way taxi fare to and from the airport is approximately \$45.00.

Yellow Cab

Phone: +1 (303) 777-7777

Website: www.yellowtrans.com

Super Shuttle

4605 Paris St.

Box #1 Suite D20

Denver, CO 80239

Phone: +1 (303) 370-1300

Toll Free: +1 (800) 258-3826

Website: www.supershuttle.com

PARKING

The Hyatt Regency Denver has both valet and self parking options available. Please contact the hotel directly for the most up to date rates available.

Rates are as follows:

Valet Parking

Daily Valet Parking.....\$17.00

Overnight Valet Parking.....\$27.00

Self-Parking

Daily Self Parking.....\$8.00

(for first hour/ \$2.00 each additional hour)

Overnight Self Parking.....\$24.00

PRESENTER INFORMATION

SPEAKER READY ROOM

Thursday through Sunday

Level 3, Agate A

ALL Oral Presenters must check in at the Speaker Ready Room at least four (4) hours prior to your scheduled presentation to confirm that your presentation is correct. When you are finished reviewing your presentation and verify it is ready, the AV personnel will queue your presentation onto the networked conference computers. The file will then be transferred to the session computer prior to the start of your talk.

You may also edit your presentation at this time. Changes will be accepted up to one (1) hour prior to the start of your session. Please note that all changes must be approved by the American Academy of CME, the accredited provider for the conference. The hours of operation of the Speaker Ready Room are as follows:

Thursday, May 14.....3:00 pm – 6:00 pm
Friday, May 15.....7:00 am – 7:00 pm
Saturday, May 16.....7:00 am – 5:00 pm
Sunday, May 17.....7:00 am – 10:00 am

POSTER PRESENTATIONS

Friday through Saturday

Level 3, Exhibit Hall, Centennial Ballroom E-H

The Welcome Reception and all breakfasts and lunches will take place in the Poster and Exhibit Hall area (Centennial Ballroom E-H). We encourage presenters to stand next to their poster during these high traffic times. We also ask that each presenter stand next to their poster on the designated day and time of their session to be available for questions. The days and times are below:

Friday, May 15, 11:30 am – 12:45 pm

Poster Session 1: *Complications*

Poster Session 2: *The Treatment Experienced Patient*

Saturday, May 16, 12:00 pm – 1:30 pm

Poster Session 3: *Testing & Linkages to Care*

Poster Session 4: *Initial Treatment for HIV Infection*

Poster Session 5: *Comprehensive Care*

All posters must be set up between 5:00 pm and 7:00 pm on Thursday, May 14th in Centennial Ballroom E-H at the Hyatt.

All posters should remain on display through Saturday at 4:00 pm. Posters must be taken down between 4:00 pm and 6:00 pm on Saturday, May 16th.

Do not leave your poster on the poster board. Posters remaining after 6:00 pm on Saturday, May 16th will be discarded.



Physicians: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Academy of CME (Academy) and ACTHIV. The Academy is accredited by the ACCME to provide continuing medical education for physicians.

The Academy designates this educational activity for a maximum of 15.75 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity has been reviewed and is acceptable for up to 15.75 Prescribed credits by the American Academy of Family Physicians.

Nurses: The American Academy of CME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

The Academy designates this educational activity for 15.75 contact hours. In order to receive your CE certificate, you must register for the conference, document attendance, and complete and return an evaluation form.



Pharmacists: The American Academy of CME, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program provides 15.75 contact hours (1.575 CEUs) of continuing education credit. ACPE Universal Program Number 297-999-09-001-L01-P. In order to obtain your statement of credit, you must register for the conference, document attendance, and complete and return an evaluation form. A statement of credit will be mailed 6-8 weeks following the conference.

Social Workers: This program is approved by the National Association of Social Workers (provider # 886476750) for 15.75 continuing education contact hours.

ANCC ACCREDITATION FEEDBACK LINE 1-866-262-9730

The Accreditation Program of the American Nurses Credentialing Center is interested in the opinions and perspectives of the participants in accredited continuing nursing education activities, **particularly** those perspectives related to the presence of perceived bias* in the continuing education. For this reason, we are now providing a toll-free telephone number. Participants may access this number at any time to:

- ▶ Tell us of any noted bias or conflict of interest in the education
- ▶ Tell us of any concerns, compliments or opinions
- ▶ Tell us of a great experience
- ▶ Tell us of an unpleasant experience
- ▶ Tell us your thoughts on the process

Just call and tell us!
1-866-262-9730

*Bias is defined as: preferential influence that causes a distortion of opinion or of facts. Commercial bias may occur when an educational activity promotes one or more product(s) (drugs, devices, services, software, hardware, etc). This definition is not all inclusive and participants may use their own interpretation in deciding if a presentation is biased.

NOTE: Statements of commercial support and/or conflict of interest disclosures do not represent bias. Such statements inform the learner that the provider has implemented a mechanism to identify and resolve all conflicts of interest prior to delivery of the educational material.

HOW TO RECEIVE CREDIT

In order to receive your CME/CE documentation of credit, please sign-in during registration. After attending the conference, you must complete and return your evaluation form to the Accreditation Information Booth, located in the conference registration area (*Level 3, Centennial Foyer*). Documentation of credit will be distributed on-site, except for the pharmacists, whose statements of credit will be mailed 6-8 weeks following the program.

If you have questions about receiving CME/CE credit for participating in this activity, please visit the CME/CE Information Booth. For CME/CE information or credit details after the conference, contact psicora@academycme.org or American Academy of CME, 186 Tamarack Circle, Skillman, NJ 08558.

EXHIBIT HALL



EXHIBIT HALL HOURS

Friday through Saturday

Level 3, Exhibit Hall, Centennial Ballroom E-H

The Exhibit Hall will be open during the following hours:

Friday, May 15.....7:30 am – 7:30 pm
 Saturday, May 16.....7:30 am – 4:00 pm

EXHIBITORS

The following is a list of exhibits as of April 10, 2009:

Company	Booth(s)
AIDSInfo.....	214
American Academy of HIV Medicine	110
Bristol-Myers Squibb.....	117
CAEAR Foundation.....	96
Centers for Disease Control & Prevention Prevention is Care Campaign.....	314
Colorado AIDS Education and Training Center	209
Department of Veterans Affairs Health Strategic Healthcare Group.....	208
Gilead Sciences, Inc.....	215
Health Research, Inc.....	309
HIV Medicine Association (HIVMA).....	308
Local Colorado Agencies	102
Merck & Co., Inc.....	217
Monogram Biosciences	99

Company	Booth(s)
National Alliance of State and Territorial AIDS Directors	306
National HIV/AIDS Clinicians' Consultation Center..	310
National Institute of Health Office of Aids Research	216
National Library of Medicine	312
National Native American AIDS Prevention Center ..	302
National Network of Prevention Training Centers.....	210
OraSure Technologies, Inc	115
Pfizer, Inc.....	114
TARGET Center	211
The Greater Denver Interfaith Alliance and The Women of Faith Health Initiative	304
The Positive Project	106
Tibotec Therapeutics	116



ACTHIV would like to thank the Centers for Disease Control & Prevention, *Prevention IS Care Campaign*, for their sponsorship support.

Detailed information about each of the exhibitors above as well as an exhibit hall floorplan can be found in the *Supporter Supplement*.

CONFERENCE AGENDA

THURSDAY, MAY 14

1:00 pm – 6:00 pm	Exhibitor Move-In	Exhibit Hall, Centennial Ballroom E-H
2:00 pm – 6:00 pm	Registration Open	Centennial Foyer
5:00 pm – 7:00 pm	Poster Setup	Exhibit Hall, Centennial Ballroom E-H

FRIDAY, MAY 15

7:00 am – 7:00 pm	Registration	Centennial Foyer
7:30 am – 7:30 pm	Exhibit Hall	Exhibit Hall, Centennial Ballroom E-H
7:30 am – 9:00 am	Breakfast	Exhibit Hall, Centennial Ballroom E-H
8:00 am – 11:30 am	HIV The Basics	Capitol Ballroom 1-3

Co-Chairs: Brian Feit, MPA, Department of Health & Human Services
Kenneth Mayer, MD, Brown University

8:00 am – 8:10 am	Welcome
8:10 am – 8:30 am	History of the Epidemic <u>Ronald O. Valdiserri, MD, MPH, U.S. Department of Veterans Affairs</u>
8:30 am – 9:00 am	Natural History of HIV Infection—Pathogenesis <u>Rajesh Gandhi, MD, Massachusetts General Hospital</u>
9:00 am – 9:30 am	Clinical Tests and Guidelines: Evolving Care/Changing Guide <u>Paul Volberding, MD, San Francisco VA Medical Center</u>
9:30 am – 10:00 am	Q &A

9:30 am – 10:00 am	Morning Refreshment Break	Capitol Foyer
--------------------	---------------------------	---------------

10:00 am – 10:30 am	Medications: Types of Antiretrovirals <u>Richard D'Aquila, MD, Vanderbilt University</u>
10:30 am – 11:00 am	Transmission/Prevention: Pathogenesis <u>Mark Thrun, MD, Denver Health Medical Center</u>
11:00 am – 11:30 am	Consumer Perspective: If you build it, will they come? What consumers really want <u>Dawn Averitt Bridge, The Well Project</u>

11:30 am – 12:45 pm	Luncheon	Exhibit Hall, Centennial Ballroom E-H
---------------------	----------	---------------------------------------

11:30 am – 12:45 pm	Posters Presentations	Exhibit Hall, Centennial Ballroom E-H
---------------------	-----------------------	---------------------------------------

Poster presenters from the following topics will be available for questions:
Topic 1: Complications
Topic 2: The Treatment Experienced Patient

12:55 pm – 2:00 pm	Opening Plenary	Centennial Ballroom A-D
--------------------	-----------------	-------------------------

12:55 pm – 1:30 pm	HIV Infection in Women — Still a Challenge <u>Kathleen Squires, MD, Jefferson Medical College of Thomas Jefferson University</u>
1:30 pm – 1:55 pm	HIV Infection in MSM of Color <u>Greg Millett, MD, Centers for Disease Control and Prevention</u>

2:00 pm – 5:00 pm Session 1: Special Challenges/Co-Morbidities/Complications Centennial Ballroom A-D

Co-Chairs: Judith Feinberg, MD, *University of Cincinnati*
William Short, MD, *Jefferson Medical College of Thomas Jefferson University*

2:00 pm – 2:30 pm Renal Disease, Hypertension and Diabetes in African-Americans
M. Keith Rawlings, MD, AIDS Arms, Inc.

2:30 pm – 3:00 pm Substance Abuse
Frederick Altice, MD, Yale University School of Medicine

3:00 pm – 3:20 pm Immune Reconstitution Inflammatory Syndrome
William Short, MD, Jefferson Medical College of Thomas Jefferson University

3:20 pm – 3:30 pm Afternoon Refreshment Break Centennial Foyer

3:30 pm – 4:10 pm Hepatitis C from Soup to Nuts
Kenneth Sherman, MD, University of Cincinnati

4:10 pm – 4:35 pm Psychiatric Issues
Andy Angelino, MD, Johns Hopkins University School of Medicine

4:35 pm – 5:00 pm Cardiovascular Disease
Carl Fichtenbaum, MD, University of Cincinnati College of Medicine

5:30 pm – 7:30 pm Welcome Reception Exhibit Hall, Centennial Ballroom E-H

SATURDAY, MAY 16

7:00 am – 5:00 pm Registration Centennial Foyer

7:30 am – 4:00 pm Exhibit Hall Exhibit Hall, Centennial Ballroom E-H

8:00 am – 9:30 am Breakfast Exhibit Hall, Centennial Ballroom E-H

9:00 am – 12:00 pm Session 2: Treatment Management Centennial Ballroom A-D

Co-Chairs: Paul Volberding, MD, *San Francisco VA Medical Center*
Douglas Ward, MD, *Dupont Circle Physicians Group*

9:00 am – 9:45 am Care of the Treatment Experienced Patient
Harry Lampiris, MD, San Francisco VA Medical Center / UCSF

9:45 am – 10:15 am Adherence
David Bangsberg, MD, Harvard University

10:15 am – 10:45 am Treatment as Prevention
Kenneth Mayer, MD, Brown University / Miriam Hospital

10:45 am – 11:00 am Morning Refreshment Break Exhibit Hall, Centennial Ballroom E-H

11:00 am – 12:00 pm Interactive Session Panel
Kenneth Lichtenstein, MD, University of Colorado at Denver & Health Sciences Center
Harry Lampiris, MD, San Francisco VA Medical Center / UCSF
Paul Volberding, MD, San Francisco VA Medical Center
Douglas Ward, MD, Dupont Circle Physicians Group

12:00 pm – 1:30 pm Luncheon Exhibit Hall, Centennial Ballroom E-H

12:00 pm – 1:30 pm Posters Presentations Exhibit Hall, Centennial Ballroom E-H

Poster presenters from the following sessions will be available for questions:
Topic 3: Testing & Linkage to Care
Topic 4: Initial Treatment for HIV Infection
Topic 5: Comprehensive Care

1:45 pm – 5:00 pm Session 3 – (Four) Concurrent Sessions

(Each Sub-Session will be offered twice)

Co-Chairs: Ronald O. Valdiserri, MD, MPH, *U.S. Department of Veterans Affairs*
 Donna Futterman, MD, *Albert Einstein College of Medicine*

{ 1:45 pm – 3:15 pm & 3:30 pm – 5:00 pm } **Sub-Session: Sexual and Reproductive Health** Centennial Ballroom A-D

Reproductive and Sexual Health Needs of Women Living with HIV
Jean Anderson, MD, John Hopkins University of School Medicine

Gay Male Sexuality and HIV/AIDS
B.R. (Simon) Rosser, PhD, MPH, LP, University of Minnesota School of Public Health

The Culture Context of Sexual Health for African American Women: What it means
 for Women Living with HIV
Laura N. Armas-Kolostroubis, MD, Texas/Oklahoma AIDS Education and Training Center

{ 1:45 pm – 3:15 pm & 3:30 pm – 5:00 pm } **Sub-Session: Substance Abuse and Mental Health** Capitol Ballroom 1-3

Reducing Alcohol and other Drug Use and Improving Adherence use among Men and Women
 Living with HIV/AIDS
Jeffrey Parsons, PhD, Hunter College at City University of New York (CUNY)

Treating Depressive Disorders and related Problems in People Living with HIV/AIDS
Stephen Ferrando, MD, Cornell University

Addressing Substance Abuse and Mental Health Needs of Patients Living with HIV Disease
Francine Cournos, MD, Columbia University

{ 1:45 pm – 3:15 pm & 3:30 pm – 5:00 pm } **Sub-Session: Adolescent and Pediatric HIV** Capitol Ballroom 4

Reproductive Tract Infections: Clinical Care and Research Initiative for HIV Infected Adolescents
Ligia Peralta, MD, University of Maryland

Improving the Diagnosis & Enhancing the Treatment of HIV-infected Gay & Lesbian Youth
Donna Futterman, MD, Albert Einstein College of Medicine

Clinical Care of HIV Disease in Childhood and Adolescence
Bret J. Rudy, MD, New York University School of Medicine

{ 1:45 pm – 3:15 pm & 3:30 pm – 5:00 pm } **Sub-Session: Viral Co-infections** Capitol Ballroom 5-7

Hepatitis B Infection and HIV
Joseph Lim, MD, Yale University School of Medicine

Rationale for HPV/Anal Cancer Screening in Patients with HIV
J. Michael Berry, MD, University of California San Francisco

3:15 pm – 3:30 pm Afternoon Break Centennial Foyer

4:00 pm – 10:00 pm Exhibitor Move-Out Exhibit Hall, Centennial Ballroom E-H

8:00 am – 11:00 am	Registration Open	Centennial Foyer
8:00 am – 9:30 am	Breakfast	Centennial Foyer
9:00 am – 11:25 am	Session 4: (Three) Skills Building Workshops	

(Each Skills Building Workshop will be offered three times. Please refer to the back of your badge and attend that color's session first, then move on to the next consecutive session. For example, if you have a yellow sticker on the back of your badge, you will attend the Cervical and Anal Paps in HIV-infected Men and Women – Practical Aspects workshop at 9:00 am, the Prevention IS Care workshop at 9:55, and the Tobacco Cessation workshop at 10:40.)

Co-Chairs: Sharon Lee, MD, Southwest Boulevard Family Health Care Services of Greater Kansas City
 Harry Lampiris, MD, San Francisco VA Medical Center
 John Brooks, MD, Centers for Disease Control and Prevention

9:00 am – 9:10 am **Welcome and Preview** Centennial Ballroom A-D

– RED –

{ 9:10 am – 9:50 am &
 9:55 am – 10:35 am &
 10:40 am – 11:20 am } **Tobacco Cessation** Capitol Ballroom 1-3

The Unique risks faced by HIV-infected smokers, the frequent opportunities for intervention that exist, and the many ways smoking cessation efforts can be effectively integrated into routine HIV care to help patients quit for life.

Damon Vidrine, DrPh, University of Texas, M.D. Anderson Cancer Center
Rachel Marks, University of Texas, M.D. Anderson Cancer Center

– YELLOW –

{ 9:10 am – 9:50 am &
 9:55 am – 10:35 am &
 10:40 am – 11:20 am } **Cervical and Anal Paps in HIV-infected Men and Women – Practical Aspects** Capitol Ballroom 4

Girls – Review of Systems for Women's Health and Continued Surveillance for Cervical Cancer Among HIV+ Women

How to Incorporate STD Screening and Prevention into HIV Care and How to Get Paid for It
Songhai Barclift, MD, Health Resources and Services Administration

Reminder How to do a Pap – Hands on – with Pelvic Models
Sharon Lee, MD, Southwest Boulevard Family Health Care Services of Greater Kansas City

Boys – The Importance of and How to do Anal Pap Smears

Implementing HPV Anal Screening for Patients with HIV
J. Michael Berry, MD, University of California San Francisco

– GREEN –

{ 9:10 am – 9:50 am &
 9:55 am – 10:35 am &
 10:40 am – 11:20 am } **"Prevention IS Care"** Capitol Ballroom 5-7

How to Incorporate STD Screening and Prevention into HIV Care
Mark Thrun, MD, Denver Health Medical Center

11:30 am – 12:00 pm	Closing Plenary	Exhibit Hall, Centennial Ballroom A-D
---------------------	------------------------	--

Where Do We Go Next? Prevention of HIV among Vulnerable Populations
Robert Fullilove, EdD, Columbia University

POSTER SESSIONS

The Program Committee has invited frontline healthcare professionals providing HIV care for adults, adolescents, children, and pregnant women to present papers in the poster program. The papers and vignettes that were selected for posters describe unique clinical experiences, new models of care and delivery, adherence interventions, testing and counseling, and other front line interventions that have enhanced the outcome of HIV disease diagnosis. **Note: CME/CE credit is not available for participation in the Poster Session.** Poster presenters will be available for discussion during the following session times:

Friday, May 15, 11:30 am – 12:45 pm

- ▶ Poster Session 1: Complications
- ▶ Poster Session 2: The Treatment Experienced Patient

Saturday, May 16, 12:00 pm – 1:30 pm

- ▶ Poster Session 3: Testing & Linkages to Care
- ▶ Poster Session 4: Initial Treatment for HIV Infection
- ▶ Poster Session 5: Comprehensive Care

KEY TO POSTER SESSION NUMBERING

Poster Session

COM = Complications

TEP = The Treatment Experienced Patient

TLC = Testing & Linkages to Care

ITI = Initial Treatment for HIV Infection

CAR = Comprehensive Care

COM-1

Poster Number

Corresponds to the order in which the poster will appear in the Exhibit Hall

An example of a poster listing is shown below. An underline represents the presenting author.

TLC – 6 Group Work for Heterosexual Couples of Mixed HIV Status

Jane Burgess, ACRN, MS, VA West Los Angeles Healthcare Center, Jeanne Saporito, LCSW, James J. Peters Medical Center

POSTER SESSIONS 1 & 2 (FRIDAY, MAY 15TH)

COM – 1 Effect of Age on the Incidence and Severity of Adverse Drug Reactions Secondary to Highly Active Antiretroviral Therapy (HAART)

Amy Hirsch, Cleveland Veterans Affairs Medical Center

COM – 2 Autoimmune Manifestations of the Immune Reconstitution Inflammatory Syndrome

William Short, MD, Jefferson Medical College of Thomas Jefferson University, Deena Athas, MD, Jefferson Medical College of Thomas Jefferson University

COM – 3 Comorbidities among Managed Care Patients with HIV and Weight Loss

Amy Phillips, EMD Serono, Inc., Aml Sklar, MPH, i3 Innovus, Eric Freedland, MD, EMD Serono, Inc., Carolyn Harley, PhD, i3 Innovus, Javeed Siddiqui, MD, University of California, Davis

COM – 4 Resolution of HIV Viremia in an HIV/HCV Co-infected Patient while on Combination HCV Therapy

Nicholas Haddad, MD, Aleda E. Lutz VA Medical Center

COM – 5 Intestinal Perforations in HIV Patients: largest case series to date of 26 patients, etiology, outcome, survival

Joseph Caperna, MD, University of California, San Diego

TEP – 1 The Safety and Efficacy of High Dose Unboosted Atazanavir in Combination with Tenofovir in HIV Patients

Jennifer Floyd, Pharm.D., BCPS, VA San Diego Healthcare System, Scott Johns, Pharm.D., BCPS, VA San Diego Healthcare System

TEP – 2 Characteristics of HIV Patients in Intermittent vs. Regular Care among a Representative Sample in Los Angeles County

Rhodri Dierst-Davies, MPH, Department of Public Health / HIV Epidemiology Program, Judith Tejero, MPH, Department of Public Health / HIV Epidemiology Program, Uchechi Acholonu, MSPH, Department of Public Health / HIV Epidemiology Program, Amy Wohl, PhD, Department of Public Health / HIV Epidemiology Program

TLC – 1 Using Capacity Planning Models to Estimate Organizational Costs of HIV Care within the United States Department of Veterans Affairs

Henry Anaya, PhD, US Department of Veterans Affairs (HRS&D), Matthew Goetz, MD, US Department of Veterans Affairs

TLC – 2 Implementing an HIV Rapid Testing Intervention for Homeless Veterans in Shelter Settings within Los Angeles County

Henry Anaya, PhD, VA Greater Los Angeles Healthcare System, Jamie Feld, BA, VA Greater Los Angeles Healthcare System, Tuyen Hoang, PhD, VA Greater Los Angeles Healthcare System

TLC – 3 Expanding HIV Rapid Testing Via Point-of-Care Paraprofessionals

Herschel Knapp, PhD, Greater Los Angeles Health Care System

TLC – 4 Qualitative Assessment of Implementing Routine Rapid HIV Testing

Henry Anaya, PhD, US Department of Veterans Affairs, Jamie Feld, BA, US Department of Veterans Affairs, Joya Golden, US Department of Veterans Affairs, Barbara Bokhour, US Department of Veterans Affairs, Herschel Knapp, PhD, US Department of Veterans Affairs

TLC – 5 HIV Rapid Testing in Emergency Departments

Jane Burgess, ACRN, MS, VA West Los Angeles Healthcare Center, Jennifer Chen, MD, Department of Veterans Affairs

TLC – 6 Group Work for Heterosexual Couples of Mixed HIV Status

Jeanne Saporito, LCSW, James J. Peters Medical Center

TLC – 7 Selecting Candidates for CCR5 Antagonist Therapy: Assessing Tropism Assay Technologies

Richard Harrigan, PhD, BC Centre for Excellence in HIV/AIDS

TLC – 8 Practical Application of the Etravirine (ETR) Weighted Genotypic Scoring System

David Anderson, Tibotec Therapeutics, Joan Cannon, Tibotec Therapeutics, Lori DeLaitsch, Tibotec Therapeutics, Lotke Tambuyzer, Tibotec BVBA, Gaston Picchio, Tibotec, Inc, James Witek, Tibotec Therapeutics

TLC – 9 Evaluation of Readiness to Implement HIV Rapid Testing in SUD Clinics

Henry Anaya, PhD, Veterans Administration, Health Services Research and Development, Hildi Hagedom, Veterans Administration, Health Services Research and Development, Jamie Feld, BA, Veterans Administration, Health Services Research and Development, S. Randal Henry, DrPH, Veterans Administration, Health Services Research and Development, Joya Golden, BA, Veterans Administration, Health Services Research and Development

ITI – 1 Enhancing the Treatment Capacity of HIV/AIDS Care Providers Serving Minority Populations through Web-based Learning: The AIDS treatment Tree Resource

Justina Ogbuokiri, HIV Outpatient Program, Ida Jean Davis, PhD, Charles Drew University

ITI – 2 Case Report of a 39 y/o Woman Initiating HAART After Lap-Band Surgery and Associated Challenges of Therapy

Jennifer Klein, MSN, Peabody Health Center / AIDS Arms, Inc., Christopher Evans, MD, Peabody Health Center / AIDS Arms, Inc., John Martin, MD, Peabody Health Center / AIDS Arms, Inc., Ejeanee Queen, MSN, Peabody Health Center / AIDS Arms, Inc., Keith Rawlings, MD, Peabody Health Center / AIDS Arms, Inc.

ITI – 3 Adherence to Darunavir/ritonavir (DRV/r) and Lopinavir/r (LPV/r) in Treatment-naïve HIV-infected Patients in ARTEMIS (AntiRetroviral Therapy with TMC114 Examined In naïve Subjects): 96-week Analysis

Guy De La Rosa, Tibotec Therapeutics, Ralph DeMasi, Tibotec, Inc., Mark Nelson, Chelsea and Westminster Hospital, Erik Smets, Tibotec BVBA, Vanitha Sekar, Tibotec, Inc., Ludo Lavreys, Tibotec BVBA

POSTER SESSION 3, 4 & 5 (CONTINUED)

ITI – 4 HIV-1 Drug Resistance in HAART Naive HIV Patients in a Southern Rural Clinic

Walter Campbell Jr., MD, LSUMC/HCSO/Bogalusa-Lallie Kemp

CAR – 1 The Impact of Integrated HIV Care on Suppression of HIV Replication

Tuyen Hoang, PhD, Greater Los Angeles VA Healthcare System

CAR – 2 The Relationship among Trauma, Self-Efficacy, and Adherence Behaviors in Veterans and Non-Veterans with HIV/AIDS

Judy K. Shaw, PhD, ANP-c, Samuel S Stratton VA Medical Center

CAR – 3 Weekly and Biweekly Subcutaneous (SC) Dosing of PRO 140 Results in Potent HIV-1 Viral Load (VL) Suppression

Paul D'Ambrosio, PhD, Progenics Pharmaceuticals, Jacob Lalezari, MD, Quest Clinical Research, Michael Saag, MD, UAB Center for AIDS Research, Jeffrey Jacobson, MD, Drexel University College of Medicine, Barry Zingman, MD, Montefiore Medical Center and the Einstein/Montefiore Center for AIDS Research, Nancy Stambler, Progenics Pharmaceuticals, Paul Maddon, MD, Progenics Pharmaceuticals, William Olson, MD, Progenics Pharmaceuticals, Stephen Morris, MD, Progenics Pharmaceuticals

CAR – 4 Providing Interdisciplinary Prevention, Treatment, Care, and Research for Youth Infected and at Risk for HIV in an Urban Setting

Mary Tanney, MSN, CRNP, MPH, AAHIVS, The Children's Hospital of Philadelphia, Christine Ambrose, LSW, The Children's Hospital of Philadelphia, Marne Castillo, PhD, The Children's Hospital of Philadelphia, Jerilynn Radcliffe, PhD, The Children's Hospital of Philadelphia, Amy Rikoon, BA, The Children's Hospital of Philadelphia, Michele Zucker, MD, The Children's Hospital of Philadelphia, Steven Douglas, MD, The Children's Hospital of Philadelphia

CAR – 5 Factors Affecting Antiretroviral Treatment Adherence in ABUTH ART Clinic Kaduna, Nigeria

Chika Amuche Ezigbo, MD, ABUTH, Shika, Zaria Nigeria, Balarabe Sani Garko, MD, Ahmadu Bello University Teaching Hospital, Zaria

CAR – 6 Successful Immunologic and Virologic Outcomes in Elderly HIV Infected Patients

Luis Manrique, MD, Rush University Medical Center/The CORE Center, Mariam Aziz, MD, Rush University Medical Center, Oluwatoyin Adeyemi, MD, Stroger Hospital of Cook County/The CORE Center

CAR – 7 Once-Daily Miconazole Mucoadhesive Buccal Tablet is an Effective and Safe Treatment for Oropharyngeal Candidiasis

Pierre Attali, MD, Bioalliance Pharma, Bertrand Dupont, MD, Hôpital Necker Paris

CAR – 8 Psychiatric Comorbidities in a National Sample of HIV-infected Veterans: Report of Preliminary Data

Diana Nurutdinova, MD, St. Louis VA Medical Center, Jeffrey Sherrer, PhD, St. Louis VA Medical Center, Timothy Chrusciel, MPH, St. Louis VA Medical Center, Angelique Zeringue, MPH, St. Louis VA Medical Center, William True, PhD, St. Louis VA Medical Center

CAR – 9 Quantitative and Qualitative Analysis of 161 patients that have Participated in a 4-part HIV Education/Adherence Module Program in an Urban HIV Clinic

Ralf Hulsmann, RN, New York Presbyterian Hospital, Bryce Clark, BSN, New York Presbyterian Hospital

CAR – 10 Development of a Clinician Support Tool on Preconception Care for HIV-infected Women

Rebecca Fry, MSN, APN, FXB Center School of Nursing UMDNJ, Carolyn Burr, FXB Center School of Nursing UMDNJ, Elaine Gross, RN, MS, CNS-C, FXB Center School of Nursing UMDNJ

CAR – 11 Weight Loss and Hypogonadism among Male Managed Care Patients with HIV

Amy Phillips, PharmD, EMD Serono, Inc., Javeed Siddiqui, MD, University of California, Davis, Ami Sklar, MPH, i3 Innovus, Eric Freedland, MD, EMD Serono, Inc., Carolyn Harley, PhD, i3 Innovus

CAR – 12 Studying Sleep Quality and Presence of Sleep Disordered Breathing in an Inner City HIV Seropositive African American Population 50 Years and Older

Supriya Mannepalli, MD, University of Florida COM, Jacksonville, Michael Sands, University of Florida COM, Jacksonville, Nilmarie Guzman, University of Florida COM, Jacksonville, Katherine Rogers, University of Florida COM, Jacksonville, Akram Khan, Oregon Health Sciences University

CAR – 13 National Quality Forum (NQF) Performance Measures for HIV/AIDS Care: The Department of Veterans Affairs (VA) Experience

Lisa Backus, Center for Quality Management in Public Health

CAR – 14 Pharmacy-Based Medication Therapy Management Services for HIV-Infected Patients in a Federally Qualified Health Center

Luis Pagan, PharmD, Florida A&M University, Michael Thompson, Florida A&M University

CAR – 15 There is A Balm in Gilead: Religious Coping among Patients on HAART

Tonia Poteat, Johns Hopkins School of Public Health, Colleen Dilorio, PhD, Emory University Rollins School of Public Health, Frances McCarty, PhD, Georgia State University Institute of Public Health



FACULTY

Frederick Altice, MD

Yale Infectious Diseases
Yale University School of Medicine

Jean Anderson, MD

Division of Gynecologic Specialties
John Hopkins University School of Medicine

Andy Angelino, MD, DFAPA

Inpatient Psychiatry
John Hopkins University School of Medicine

Laura N. Armas-Kolostroubis, MD

Texas/Oklahoma AIDS Education and Training Center

Dawn Averitt Bridge

The Well Project

David Bangsberg, MD, MPH

Harvard University

Songhai Barclift, MD

Health Resources and Services Administration

J. Michael Berry, MD

University of San Francisco California

Francine Cournos, MD

Columbia University

Richard D'Aquila, MD, FIDSA

Vanderbilt University

Stephen Ferrando, MD

Department of Psychiatry
Cornell University

Carl J. Fichtenbaum, MD

University of Cincinnati College of Medicine

Robert Fullilove, EdD

Mailman School of Public Health
Columbia University

Donna Futterman, MD

Adolescent AIDS Program
Montefiore Medical Center
Albert Einstein College of Medicine

Rajesh Gandhi, MD

Massachusetts General Hospital

Harry Lampiris, MD

San Francisco VA Medical Center / UCSF

Sharon Lee, MD

Department of Family Medicine
Southwest Boulevard Family Health Care Services of Greater
Kansas City

Kenneth Lichtenstein, MD

University of Colorado at Denver and Health Sciences Center
Division of Infectious Diseases
National Jewish Medical and Research Center

Joseph Lim, MD

Section of Digestive Diseases
Yale University School of Medicine

Rachel Marks

Department of Behavioral Science
University of Texas M.D. Anderson Cancer Center

Kenneth Mayer, MD

Infectious Disease Division
Brown University
Miriam Hospital

Greg Millett, MD

Division of HIV/AIDS Prevention
Centers for Disease Control and Prevention

Jeffrey Parsons, PhD

Department of Psychology
Hunter College at City University of New York (CUNY)

Ligia Peralta, MD, FAAP, FSAM

Division of Adolescent and Young Adult Medicine
Adolescent HIV Program
University of Maryland

M. Keith Rawlings, MD

Peabody Health Center
AIDS Arms, Inc.

B.R. (Simon) Rosser, PhD, MPH, LP

Division of Epidemiology and Community Health
University of Minnesota School of Public Health

Bret J. Rudy, MD

New York University School of Medicine

Kenneth Sherman, MD, PhD, FACP

University of Cincinnati

William Short, MD

Jefferson Medical College
Thomas Jefferson University

Kathleen E. Squires, MD

Jefferson Medical College
Thomas Jefferson University

Mark Thrun, MD

Denver Health Medical Center

Ronald Valdiserri, MD, MPH

Public Health Strategic Healthcare Group
U.S. Department of Veterans Affairs

Damon J. Vidrine, DrPH

Department of Behavioral Science
University of Texas M.D. Anderson Cancer Center

Paul Volberding, MD

Department of Medicine
San Francisco VA Medical Center

FINANCIAL DISCLOSURE OF CONFLICTS OF INTEREST

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures are listed below.

PROGRAM COMMITTEE

Erika Aaron, CRNP, MSN

▶ Erika Aaron, CRNP, MSN, discloses she has received grant research support for which she was the PI from Boehringer Ingelheim Pharmaceuticals, and the funds were paid to Drexel College of Medicine.

Arlene D. Bardequez, MD, MPH

▶ Arlene D. Bardequez, MD, MPH, has no relevant financial disclosure to make.

James Braun, DO

▶ James Braun, DO, has no relevant financial disclosure to make.

Gina M. Brown, MD

▶ Gina M. Brown, MD, has no relevant financial disclosure to make.

Victoria Cargill, MD, MSCE

▶ Victoria Cargill, MD, MSCE, has no relevant financial disclosure to make.

Tommy Chesbro, MHR, AASECT

▶ Tommy Chesbro, MHR, AASECT, has no relevant financial disclosure to make.

Steven Deeks, MD

▶ Steven Deeks, MD, discloses he has participated as an ad hoc advisor to GlaxoSmithKline Pharmaceuticals, Roche, and Schering-Plough. He has served as the PI for studies funded in part Bristol-Myers Squibb, Gilead Sciences, Merck & Co., Monogram, and Pfizer, and the funds were paid to University of California, San Francisco.

Judith Feinberg, MD

▶ Judith Feinberg, MD, discloses she has been a member of the advisory board for marketing purposes for Boehringer Ingelheim, Bristol-Myers Squibb and Tibotec, and for scientific information for Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline Pharmaceuticals, Merck & Co., Tibotec, and Pfizer. She has been a

consultant for clinical trial design with Bio-availability Systems (unpaid), Boehringer Ingelheim, Koronis Pharmaceuticals, and Tibotec. She has received grant research support for which she was the PI from Boehringer Ingelheim, Bioavailability Systems, Bristol-Myers Squibb, Neurogesx, Pfizer, Roche, Theratechnology, Tibotec, and the funds were paid to University of Cincinnati. She has been on the promotional speakers' bureaus for Bristol-Myers Squibb, Boehringer Ingelheim, Gilead Sciences, Merck & Co., Pfizer and Tibotec.

Brian Feit, MPA

▶ Brian Feit, MPA, is a shareholder in Medtronic.

Gerald Friedland, MD

▶ Gerald Friedland, MD, discloses he has received grant research support from Merck & Co., and the funds were paid to his institution.

Donna Futterman, MD

▶ Donna Futterman, MD, discloses she has been a consultant for Gilead Sciences. She has been the PI on a research grant from Erasure, and the PI on an educational grant from Gilead Sciences and Orasure, and the funds were paid to Montefiore Medical Center.

Harold Henderson, MD

▶ Harold Henderson, MD, has no relevant financial disclosure to make.

Brian Hujdich, BA

▶ Brian Hujdich, BA, has no relevant financial disclosure to make.

John JD Juchniewicz, MCIS

▶ John JD Juchniewicz, MCIS, was a shareholder in Johnson & Johnson through February 2008.

Natalie Kirkwood, BSN, JD

▶ Natalie Kirkwood, BSN, JD, has no relevant financial disclosure to make.

Harry Lampiris, MD

▶ Harry Lampiris, MD, discloses he has served on the advisory board for scientific information for Abbott, Boehringer Ingelheim, and Monogram Biosciences. He has received grant research support from Gilead Sciences (PI), Pfizer (PI), and Roche (PI), and the funds were paid to his institution. He has served on the promotional speaker's bureaus of Boehringer Ingelheim, Merck & Co, and Monogram Biosciences.

Sharon Lee, MD

▶ Sharon Lee, MD, has no relevant financial disclosure to make.

Kenneth A. Lichtenstein, MD

▶ Kenneth A. Lichtenstein, MD, discloses has served on the advisory boards for scientific information for Bristol-Myers Squibb and Gilead Sciences, and for marketing for Abbott, Merck, and Tibotec. He has served as a consultant on clinical trial design for Abbott, Bristol-Myers Squibb, Gilead Sciences, and Merck & Co. He has received grant research support from Merck & Co (PI), Pfizer, and TaiMed, and the funds were paid to National Jewish Health.

Kenneth H. Mayer, MD

▶ Kenneth H. Mayer, MD, discloses he has served on the advisory boards for scientific information for Merck & Co. and Pfizer. He was the PI for grant research support from Gilead Sciences and Merck & Co., and the funds were paid to Fenway Community Health. He has served on the promotional speaker's bureaus of Boehringer Ingelheim, Gilead Sciences, Merck & Co, and Tibotec.

PROGRAM COMMITTEE (CONTINUED)

Sondra L. Moylan, MS, RN

▶ Sondra L. Moylan, MS, RN, has no relevant disclosure to make.

Tonia Poteat, MMSc, MPH, PA

▶ Tonia Poteat, MMSc, MPH, PA, discloses she has served on the patient programs speaker's bureau for Boehringer Ingelheim.

Anita E. Radix, MD

▶ Anita E. Radix, MD, discloses she is a member of the advisory board for scientific information for Gilead Sciences. She is a member of the promotional speaker's bureau for GlaxoSmithKline Pharmaceuticals.

M. Keith Rawlings, MD

▶ M. Keith Rawlings, MD, discloses he is a member of the advisory boards for marketing purposes for Abbott, Gilead Sciences, GlaxoSmithKline Pharmaceuticals, and Tibotec Therapeutics. He is a member of the advisory board for scientific information for Ardea Biosciences. He is a member of the promotional speaker's bureaus of Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Pharmaceuticals, Pfizer, and Tibotec Therapeutics.

David Rimland, MD

▶ David Rimland, MD, discloses the Atlanta Research and Education Foundation, for which he serves as Principal Investigator, has received grant research support from Bristol-Myers Squibb.

William R. Short, MD

▶ William R. Short, MD, discloses he is a member of the advisory board for marketing purposes for Tibotec. He is a member of the advisory boards for scientific information for Abbott, Gilead Sciences, and Tibotec. He is a member of the promotional speaker's bureaus for Gilead Sciences, GlaxoSmithKline Pharmaceuticals, Merck & Co, and Tibotec.

Kathleen E. Squires, MD

▶ Kathleen E. Squires, MD, discloses that she served as a member of the advisory board for scientific information for Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Pharmaceuticals, Koronis Pharmaceuticals, Schering-Plough, Tibotec, and Tobira Therapeutics. She has served as a consultant related to clinical trials for Merck & Co. She has received grant research support for which she is the national PI/co-PI or site PI from Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline Pharmaceuticals, Koronis Pharmaceuticals, Merck & Co, Schering Plough, and Tibotec, and the funds were paid to Thomas Jefferson University.

Melanie Thompson, MD

▶ Melanie Thompson, MD, discloses she has served on the advisory boards for scientific information and was a consultant for clinical trial design for GlaxoSmithKline, Panacos Pharmaceuticals, Pfizer, Progenics Pharmaceuticals, and Tibotec. The AIDS Research Consortium of Atlanta, for which she serves as Principal Investigator, has received grant research support from Abbott Laboratories, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline Pharmaceuticals, Gilead Sciences, Koronis Pharmaceuticals, Merck Research Laboratories, Ora-Sure, Panacos Pharmaceuticals, Pfizer, Progenics Pharmaceuticals, Roche Laboratories, Roche Molecular Systems, Theratechnologies, Tibotec, and Tobira Therapeutics, and the funds were paid to AIDS Research Consortium of Atlanta. She received one scientific lecture sponsorship from GlaxoSmithKline Pharmaceuticals. She has served as a member of a data safety monitoring board for Tibotec.

Glenn J. Treisman, MD, PhD

▶ Glenn J. Treisman, MD, PhD, discloses he has served on the promotional speaker's bureaus of Abbott and Boehringer Ingelheim.

Paul Volberding, MD

▶ Paul Volberding, MD, discloses he has served on the advisory boards for scientific information for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Pharmaceuticals, Merck & Co, Pfizer, Schering-Plough, and Tobira Therapeutics. He has served on endpoint adjudication committees for Schering-Plough. He has served as an expert witness in a lawsuit against Abbott. He has served as the chair of a data safety monitoring board for TaiMed Biologics.

Douglas Ward, MD

▶ Douglas Ward, MD, discloses he has served on the advisory boards for marketing purposes for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Pharmaceuticals, and Tibotec. He has served on the advisory board for scientific information for Tibotec. He has received grant research support for which he was the PI from Boehringer Ingelheim, GlaxoSmithKline Pharmaceuticals, Gilead Sciences, Koronis Pharmaceuticals Merck & Co, Pharmasset, Roche and TaiMed Biologics, and the funds were paid to Dupont Circle Physicians Group. He has served on the promotional speaker's bureaus for Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline Pharmaceuticals, Merck & Co, Monogram Biosciences, Pfizer, and Roche.

Barbara A. Young, MSW, LCSW, LCADC, SAC

▶ Barbara A. Young, MSW, LCSW, LCADC, SAC, has no relevant disclosures to make.

FEDERAL SCIENTIFIC COLLABORATIVE PANEL

Songhai Barclift, MD

▶ Songhai Barclift, MD, has no relevant financial disclosure to make.

Christopher Bates, MPA

▶ Christopher Bates, MPA, has no relevant financial disclosure to make.

John T. Brooks, MD

▶ John T. Brooks, MD, has no relevant financial disclosure to make.

Lawrence Deyton, MSPH, MD

▶ Lawrence Deyton, MSPH, MD, has no relevant financial disclosure to make.

Robert Eisinger, PhD

▶ Robert Eisinger, PhD, has no relevant financial disclosure to make.

Catherine Godfrey, MD

▶ Catherine Godfrey, MD, has no relevant financial disclosure to make.

Christopher M. Gordon, PhD

▶ Christopher M. Gordon, PhD, has no relevant financial disclosure to make.

Newton E. Kendig, RADM

▶ Newton E. Kendig, RADM, has no relevant financial disclosure to make.

Jag H. Khalsa, PhD

▶ Jag H. Khalsa, PhD, has no relevant financial disclosure to make.

Lynne M. Mofenson, MD

▶ Lynne M. Mofenson, MD, has no relevant financial disclosure to make.

Mostafa Nokta, MD, PhD

▶ Mostafa Nokta, MD, PhD has no relevant financial disclosure to make.

Ronald O. Valdiserri, MD, MPH

▶ Ronald O. Valdiserri, MD, MPH, has no relevant financial disclosure to make.

FACULTY

Frederick Altice, MD

▶ Frederick Altice, MD, has served on the advisory boards for scientific information for Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, and Roche. He has received supplemental grant research support for which he is the PI from Boehringer Ingelheim, and the funds were paid to Yale University. He has served on the promotional speaker's bureaus of Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Merck and Co., and Roche.

▶ Frederick Altice, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Jean Anderson, MD

▶ Jean Anderson, MD, discloses she has served on the promotional speaker's bureaus of Abbott and GlaxoSmithKline.

▶ Jean Anderson, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Andrew F. Angelino, MD, DFAPA

▶ Andrew F. Angelino, MD, DFAPA, discloses he has served on the advisory board for scientific information for Abbott Laboratories. He has served on the promotional speaker's bureaus of Boehringer Ingelheim and Pfizer.

▶ Andrew F. Angelino, MD, DFAPA, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Laura N. Armas-Kolostroubis, MD

▶ Laura N. Armas-Kolostroubis, MD, has no relevant financial disclosure to make.

▶ Laura N. Armas-Kolostroubis, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Dawn Averitt Bridge

▶ Dawn Averitt Bridge discloses that she has been a consultant for clinical trial design for Boehringer Ingelheim, Merck & Co., and Tibotec, and consulting for program/advocacy for Bristol-Myers Squibb. She has received honoraria for speaking or for community advisory boards from Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., and Gilead Sciences.

▶ Dawn Averitt Bridge does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

David Bangsberg, MD

▶ David Bangsberg, MD, has no relevant financial disclosure to make.

▶ David Bangsberg, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Songhai Barclift, MD

▶ Songhai Barclift, MD, has no relevant financial disclosure to make.

▶ Songhai Barclift, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

J. Michael Berry, MD

▶ J. Michael Berry, MD, discloses he has received grant research support from Merck & Co (not HIV related).

▶ J. Michael Berry, MD, intends to discuss non-FDA-approved use of infrared

coagulators for treatment of high-grade anal neoplasia, and use of fluorouracil cream as adjunctive or primary therapy for high-grade anal neoplasia.

Francine Cournos, MD

▶ Francine Cournos, MD, has no relevant financial disclosure to make.

▶ Francine Cournos, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Richard T. D'Aquila, MD, FIDSA

▶ Richard T. D'Aquila, MD, FIDSA, discloses he has served on the advisory board for marketing purposes for Tibotec Therapeutics; he has served on the advisory boards for scientific information for Boehringer Ingelheim, Gilead Sciences, and Merck & Co. He has received grant research support from GlaxoSmithKline (PI for investigator-initiated grant), Merck & Co. (PI for investigator-initiated grants), Virco (PI for database research collaboration), and the funds were paid to Vanderbilt University.

▶ Richard T. D'Aquila, MD, FIDSA, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Stephen Ferrando, MD

▶ Stephen Ferrando, MD, discloses he has served on the advisory board for scientific information for Abbott. He has served on the promotional speaker's bureaus for AstraZeneca and Pfizer. He has intellectual property/patents with AstraZeneca.

FACULTY (CONTINUED)

▶ Stephen Ferrando, MD, intends to discuss non-FDA-approved use of testosterone replacement therapy and dehydroepiandrosterone.

Carl Fichtenbaum, MD

▶ Carl Fichtenbaum, MD, discloses he has received grant research support for which he was the PI from Abbott, Gilead Sciences, Pfizer, rogenics, and Tibotec Therapeutics, and the funds were paid to University of Cincinnati. Carl Fichtenbaum, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Robert Fullilove, EdD

▶ Robert Fullilove, EdD, has no relevant financial disclosures to make.

Donna Futterman, MD

▶ Donna Futterman, MD, discloses she has been a consultant for Gilead Sciences. She has been the PI on a research grant from Orasure, and the funds were paid to Montefiore Medical Center. She has received an unrestricted educational grant from Gilead Sciences.

▶ Donna Futterman, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Raj T. Gandhi, MD

▶ Raj T. Gandhi, MD, discloses that he has served on the advisory board for scientific information for GlaxoSmithKline. He has received unrestricted research and educational grant support from Abbott, Gilead Sciences, and Tibotec Therapeutics; he was the PI for a research grant from Tibotec Therapeutics, and the funds were paid to Massachusetts General Hospital. Raj T. Gandhi, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Harry Lampiris, MD

▶ Harry Lampiris, MD, discloses he has served on the advisory board for scientific information for Abbott, Boehringer Ingelheim, and Monogram Biosciences. He has received grant research support

from Gilead Sciences (PI), Pfizer (PI), and Roche (PI), and the funds were paid to his institution. He has served on the promotional speaker's bureaus of Boehringer Ingelheim, GlaxoSmithKline, Merck & Co, and Monogram Biosciences. Harry Lampiris, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Sharon D. Lee, MD

▶ Sharon D. Lee, MD, has no relevant financial disclosure to make.

▶ Sharon D. Lee, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Kenneth A. Lichtenstein, MD

▶ Kenneth A. Lichtenstein, MD, discloses he has served on the advisory boards for scientific information for Bristol-Myers Squibb and Gilead Sciences, and for scientific and marketing information for Abbott, Merck, and Tibotec. He has served as a consultant on clinical trial design for Abbott, Bristol-Myers Squibb, Gilead Sciences, Merck & Co, and Tibotec. He has received grant research support from Merck & Co (PI), Pfizer, and TaiMed, and the funds were paid to National Jewish Health. Kenneth A. Lichtenstein, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Joseph Lim, MD

▶ Joseph Lim, MD, discloses he has received grant research support for which he was the PI from Bristol-Myers Squibb, Debiovision, Gilead Sciences, GlaxoSmithKline, Globeimmune, and Romark, and the funds were paid to Yale University School of Medicine.

▶ Joseph Lim, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Rachel Marks

▶ Rachel Marks has no relevant financial disclosure to make.

▶ Rachel Marks does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Kenneth H. Mayer, MD

▶ Kenneth H. Mayer, MD, discloses he has served on the advisory boards for scientific information for Merck & Co. and Pfizer. He was the PI for grant research support from Gilead Sciences and Merck & Co., and the funds were paid to Fenway Community Health. He has served on the promotional speaker's bureaus of Boehringer Ingelheim, Gilead Sciences, Merck & Co, and Tibotec.

▶ Kenneth H. Mayer, MD, intends to discuss non-FDA-approved uses of antiretrovirals for post-exposure prophylaxis and their effects on decreasing HIV transmission.

Greg Millett, MD

▶ Greg Millett, MD, has no relevant disclosures to make.

▶ Greg Millett, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Jeffrey T. Parsons, PhD

▶ Jeffrey T. Parsons, PhD, has no relevant financial disclosure to make.

▶ Jeffrey T. Parsons, PhD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Ligia Peralta, MD

▶ Ligia Peralta, MD, has no relevant financial disclosure to make.

▶ Ligia Peralta, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

M. Keith Rawlings, MD

▶ M. Keith Rawlings, MD, discloses he is a member of the advisory board for scientific information for Ardea Biosciences. He is a member of the advisory boards for marketing purposes for Abbott, Gilead Sciences, GlaxoSmithKline, and Tibotec Therapeutics. He is a consultant for marketing purposes for Abbott and GlaxoSmithKline. He is a member of the promotional speaker's bureaus of Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Pfizer, and Tibotec Therapeutics.

▶ M. Keith Rawlings, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

BR Rosser, PhD

▶ BR Rosser, PhD, has no relevant financial disclosure to make.

▶ BR Rosser, PhD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Brett J. Rudy, MD

▶ Brett J. Rudy, MD, has no relevant disclosures to make.

▶ Brett J. Rudy, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Kenneth Sherman, MD

▶ Kenneth Sherman, MD, has served on the advisory boards for scientific information for Bristol-Myers Squibb, Merck & Co, SciClone Pharmaceuticals, and Vertex Pharmaceuticals. He has been a consultant for clinical trial design for SciClone Pharmaceuticals and Valeant Pharmaceuticals. He has received grant research support from Bristol-Myers Squibb, Gilead Sciences, Human Genome Sciences, Roche, Schering-Plough, SciClone Pharmaceuticals, Vertex Pharmaceuticals, and the funds were paid to his institution. He has intellectual property/patents that were assigned to the US Army.

▶ Kenneth Sherman, MD, intends to discuss non-FDA-approved uses of peg-interferon and ribavirin, and investigational uses of the following experimental agents: STAT-C agents for HCV.

William R. Short, MD

▶ William R. Short, MD, discloses he is a member of the advisory board for marketing purposes for Tibotec. He is a member of the advisory boards for scientific information for Abbott, Gilead Sciences, and Tibotec. [He is a member of the promotional speaker's bureaus for Gilead Sciences, GlaxoSmithKline, Merck & Co, and Tibotec. William R. Short, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Kathleen Squires, MD

▶ Kathleen E. Squires, MD, discloses that she served as a member of the advisory board for scientific information for Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Koronis Pharmaceuticals, Schering-Plough, and Tobira Therapeutics; and has served on advisory boards for scientific information and marketing purposes for Tibotec Therapeutics. She has served as a consultant related to clinical trials for GlaxoSmithKline, Merck & Co, Schering-Plough and Tibotec Therapeutics. She has received grant research support for which she is the national PI/co-PI or site PI from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Koronis Pharmaceuticals, Merck & Co, Pfizer, Schering Plough, and Tibotec Therapeutics, and the funds were paid to Thomas Jefferson University.

▶ Kathleen Squires, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Mark Thrun, MD

▶ Mark Thrun, MD, has no relevant financial disclosure to make.

▶ Mark Thrun, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Ronald O. Valdiserri, MD, MPH

▶ Ronald O. Valdiserri, MD, MPH, has no relevant financial disclosure to make.

▶ Ronald O. Valdiserri, MD, MPH, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Damon J. Vidrine, DrPH

▶ Damon J. Vidrine, PhD, has no relevant financial disclosure to make.

▶ Damon J. Vidrine, PhD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

Paul Volberding, MD

▶ Paul Volberding, MD, discloses he has served on the advisory boards for scientific information for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck & Co, Pfizer, Schering-Plough, and Tobira Therapeutics. He has served on endpoint adjudication committees for Schering-Plough. He has received an educational grant from GlaxoSmithKline-Italia. He has served as an expert witness in a lawsuit against Abbott. He has served as the chair of a data safety monitoring board for Merck & Co. and TaiMed Biologics.

▶ Paul Volberding, MD, does not intend to discuss any non-FDA-approved or investigational uses of any product/device.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the American Academy of CME or American Conference for the Treatment of HIV. Before prescribing any medication, physicians should consult primary references and full prescribing information. Please refer to official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this activity.

The American Academy of CME requires all faculty/authors to note the level of evidence for any patient care recommendation made during their presentations.

© 2009 American Academy of CME and American Conference for the Treatment of HIV



American Academy of CME, Inc.
186 Tamarack Circle • Skillman, NJ 08558
P: +1 (609) 921-6622 • F: +1 (609) 921-6428
Website: www.academycme.org



ACTHIV
THE AMERICAN CONFERENCE
FOR THE TREATMENT OF HIV

c/o Courtesy Associates
2025 M Street NW, Suite 800 • Washington, DC 20036
P: +1 (202) 973-8658 • F: +1 (202) 331-0111
Email: ACTHIV@courtesyassoc.com
Website: www.ACTHIV.org